Research programme: cancer therapeutics - Protox Therapeutics

Drug Profile

Research programme: cancer therapeutics - Protox Therapeutics

Alternative Names: LH1; Lung-H1; PORxin™ Ab; PORxin™ antibody fusion constructs

Latest Information Update: 09 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Research Council Canada; University of Victoria
  • Developer Sophiris Bio
  • Class
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Apr 2012 Protox Therapeutics is now called Sophiris Bio
  • 02 Apr 2012 Discontinued for Cancer in Canada (Parenteral)
  • 11 Jun 2007 Early research for cancer is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top